Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.72 |
| ▸ | HTR2B | P41595 | 16/20 | 0.72 |
| ▸ | HTR1A | P08908 | 3/20 | 0.72 |
| ▸ | DRD2 | P14416 | 3/20 | 0.72 |
| ▸ | HTR1D | P28221 | 2/20 | 0.72 |
| ▸ | HTR1B | P28222 | 2/20 | 0.72 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814256 | 1.00 | HTR6 (0.72) | HTR6HTR2BHTR1ADRD2HTR1D | |
| Hydrochloric Acid SCHEMBL1815906 | 0.99 | HTR6 (0.70) | HTR6HTR2BHTR1ADRD2HTR1D | |
| SCHEMBL1813748 | 0.94 | HTR6 (0.71) | HTR6HTR2BHTR1ADRD2HTR1D | |
| Hydrochloric Acid SCHEMBL1816016 | 0.93 | HTR6 (0.69) | HTR6HTR2BHTR1ADRD2HTR1D | |
| Hydrochloric Acid SCHEMBL3549339 | 0.93 | HTR6 (0.69) | HTR6HTR2BHTR1ADRD2HTR1D | |
| SCHEMBL1814543 | 0.92 | HTR6 (0.70) | HTR6HTR2BHTR1ADRD2HTR1D | |
| SCHEMBL1812152 | 0.86 | HTR6 (0.73) | HTR6HTR2BHTR1ADRD2HTR1D | |
| SCHEMBL1811658 | 0.86 | HTR6 (0.73) | HTR6HTR2BHTR1ADRD2HTR1D | |
| SCHEMBL1811655 | 0.86 | HTR6 (0.73) | HTR6HTR2BHTR1ADRD2HTR1D | |
| SCHEMBL1815357 | 0.85 | HTR6 (0.53) | HTR6HTR2BHTR1ADRD2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939520-B2 | Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2011-05-10 | — | — | US | claimed |
| EP-2158195-A1 | 5- (AMINOAZACYCLYL) -3-SULFONYL-LH- INDAZOLES AS 5-HYDROXYTRYPTAMINE- 6 LIGANDS FOR THE TREATMENT OF CNS DISORDERS | Wyeth LLC (US) | 2010-03-03 | — | — | EP | claimed |
| US-20080293688-A1 | AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-27 | — | — | US | claimed |
| WO-2008144299-A1 | 5- (AMINOAZACYCLYL) -3-SULFONYL-LH- INDAZOLES AS 5-HYDROXYTRYPTAMINE- 6 LIGANDS FOR THE TREATMENT OF CNS DISORDERS | WYETH (US) | 2008-11-27 | — | — | WO | claimed |
| US-7939520-B2 | Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2158195-A1 | 5- (AMINOAZACYCLYL) -3-SULFONYL-LH- INDAZOLES AS 5-HYDROXYTRYPTAMINE- 6 LIGANDS FOR THE TREATMENT OF CNS DISORDERS | Wyeth LLC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20080293688-A1 | AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008144299-A1 | 5- (AMINOAZACYCLYL) -3-SULFONYL-LH- INDAZOLES AS 5-HYDROXYTRYPTAMINE- 6 LIGANDS FOR THE TREATMENT OF CNS DISORDERS | WYETH (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293688-A1 | AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR3B, HTR5A | HTR6 1/4885HTR2B 14/4885HTR1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.